Results
|
|
1.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
|
2.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
|
3.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
